Pembrolizumab-related toxicity in patients with advanced melanoma
New Zealand Medical Journal · 2025
DOI: 10.26635/6965.6777 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Zealand Medical Journal, 2025. Verfasst von Florence de Roo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Fellow, Southern Blood and Cancer Service, Health New Zealand - Te Whatu Ora Southern, Dunedin Hospital, Dunedin, New Zealand; PhD C…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Melanoma, Antineoplastic Agents, Immunological, Skin Neoplasms.
Abstract (Originalsprache)
aim: Pembrolizumab has revolutionised the treatment of melanoma. Immune checkpoint inhibitors (ICI) are well tolerated in trials, but the real-world incidence of toxicities and their management are not well described. We investigated the incidence and management of toxicities in New Zealand. methods: A retrospective review was conducted on patients with metastatic melanoma treated with pembrolizumab at Wellington and Waikato Hospitals between March 2016 and September 2021. The occurrence, severity and management of toxicities was recorded. results: Of the 273 patients, 42% experienced treatment-related toxicity. Seventy-five percent of toxicities were grade 1/2 (mild), 25% grade 3/4 (moderate or life-threatening) and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology Fellow, Southern Blood and Cancer Service, Health New Zealand - Te Whatu Ora Southern, Dunedin Hospital, Dunedin, New Zealand; PhD Candidate, Department of Pathology, University of Otago, Dunedin, New Z…
- Medical Registrar, Wellington Hospital, New Zealand.
- General Physician, Department of General Medicine, Waikato Hospital, Hamilton, New Zealand.
- Consultant Medical Oncologist, Medical Oncology Department, Waikato Hospital, Hamilton, New Zealand.
- Consultant Medical Oncologist, Wellington Blood and Cancer Centre, Wellington Hospital, Wellington, New Zealand; Senior Lecturer, Department of Medicine, University of Otago, Wellington, New Zealand; Department of Oncol…
Zitieren
APA
de Roo, F., Singh, A., Zheng, E., Tan, A., & Wong, A. N. M. (2025). Pembrolizumab-related toxicity in patients with advanced melanoma. New Zealand Medical Journal. https://doi.org/10.26635/6965.6777
Vancouver
de Roo F, Singh A, Zheng E, Tan A, Wong ANM. Pembrolizumab-related toxicity in patients with advanced melanoma. New Zealand Medical Journal. 2025. doi:10.26635/6965.6777
BibTeX
@article{deRoo2025,
author = {de Roo, Florence and Singh, Amritpreet and Zheng, Eric and Tan, Alvin and Wong, Annie N M},
title = {Pembrolizumab-related toxicity in patients with advanced melanoma},
journal = {New Zealand Medical Journal},
year = {2025},
doi = {10.26635/6965.6777}
}
EUVIMED